Medical professionals
Empowering clinicians with pioneering research and treatment insights
We continue to discover, assess and develop new compounds and biologics with therapeutic and diagnostic promise for neurodegenerative diseases caused by protein aggregation.
Neurodegenerative disorders
Our groundbreaking drug could treat a range of conditions that share common pathological features.
Tau and tau pathology
Healthy tau protein is critical for stabilising cell structure in the brain, but can disrupt neuronal function if it misfolds.
Neurofilament Light Chain (NfL)
This biomarker for damaged brain cells can be a powerful tool for measuring and predicting disease progression.
Tau inhibition
Our product, HMTM, belongs to a class of drugs known as Tau Aggregation Inhibitors (TAIs). These work by preventing and dissolving tau aggregates, to preserve the normal tau function essential for a healthy brain.
Mild cognitive impairment
Recognising MCI as an early predictor for dementia is critical to engaging patients and carers as early as possible.
Alzheimer’s disease
Discover the impact of our drug, HMTM, on the progression of Alzheimer’s disease, from the results of our most recent clinical trial involving 3,000 participants.
Frontotemporal dementia
Frontotemporal dementia and Alzheimer’s share a similar pathology but affect different regions of the brain. Through its active ingredient which targets two types of proteins, our drug could provide a treatment for both.